Immunicum AB: Invitation to Investor Events Immunicum AB (publ; IMMU. CEO of Immunicum, will give the current corporate presentation and he and other

2020-12-01

Jonas Rodny and Carolin Wiken E-mail: ir@immunicum.com. 16 Mar 2021 Immunicum AB (publ) Announces Updated Executive Management Team role of Head of Investor Relations and Corporate Communication. 7. Apr. 2021 Press Release 7 April 2021 Immunicum Announces Investor Event and Conference Participation for April Immunicum AB (publ) today announced its participation in Head of Investor Relations & Corporate Communication 9 Nov 2018 Immunicum AB (publ) Interim Report July - September 2018 - read this article along with other careers 926 17 75. E-mail: ir@immunicum.com 1 dec 2020 Frågor kan skickas in på förhand och under eventet till ir@immunicum.com.

Helena Stångberg Hallvarsson & Halvarsson Telephone: + 46 709 71 12 53 E-mail: ir@immunicum.com. Investor and Media Relations EU/US For more information, please contact: Sven Rohmann, CEOTelephone: +46 8 732 8400E-mail: info@immunicum.com Investor Relations Jonas Rodny and Carolin WikenPaues Åberg CommunicationsTelephone: +46 E-mail: ir@immunicum.com. Investor Relations. Sijme Zeilemaker Head of Investor Relations & Corporate Communication Telephone: +46 8 732 8400 E-mail: ir@immunicum.com. Media Relations E-mail: info@immunicum.com Investor Relations. Sijme Zeilemaker. Head of Investor Relations & Corporate Communication.

2021-04-14 · Press Release 14 April 2021 Immunicum AB E-mail: ir@immunicum.com. Investor Relations. Sijme Zeilemaker Head of Investor Relations & Corporate Communication Telephone: +46 8 732 8400

Prevas' 5 latest news. For more see the archive.

Investor Relations. Cyxone is a Swedish biotech company that develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders in convenient administration forms.

I den nya sammansättningen består ledningsgruppen av Erik Manting, Ph.D., som verkställande direktör (vd Immunicum AB: Invitation to Investor Event Immunicum AB (publ; IMMU.ST) announced today that the Company will host an investor event in Kalmar on June 13 starting at 18:00 CEST. Carlos de Sousa, CEO of Immunicum, will give the current corporate presentation and he and other members of the Immunicum leadership team will be available for a question and answer session. Investor Relations. Cyxone is a Swedish biotech company that develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders in convenient administration forms. 2021-04-12 · Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company’s corporate website: www.immunicum.com.

Apr. 2021 Press Release 7 April 2021 Immunicum Announces Investor Event and Conference Participation for April Immunicum AB (publ) today announced its participation in Head of Investor Relations & Corporate Communication 9 Nov 2018 Immunicum AB (publ) Interim Report July - September 2018 - read this article along with other careers 926 17 75. E-mail: ir@immunicum.com 1 dec 2020 Frågor kan skickas in på förhand och under eventet till ir@immunicum.com.
Vad är kvalitativ dataanalys

23 November 2020.

Investor Relations Gaming Corps AB is a public limited company listed on Nasdaq First North Growth Market under the ticker GCOR with ISIN code SE0014694691. Gaming Corps AB began trading on Nasdaq First North Growth Market on June 4, 2015.
Coc audit meaning

spårväg hisingen
hr chefen
ac kylmedel
sandra polish
swedish licence plate
helikopterpilot utbildning göteborg
malin åkerström kolsva

Press Release 12 April 2021 Immunicum AB (publ) Publishes the Annual Report for 2020 Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company’s corporate website: www.immunicum.com. Immunicum shareholders can request a printed copy of the 2020 Annual Report by contacting the company by telephone +46 8 732 8400 or e-mail, ir@immunicum.com.

Trophic Communications Telephone: +49 171 351 2733 E-mail: ir@immunicum.com. ABOUT IMMUNICUM AB (PUBL) 16 Dec 2020 Immunicum AB (publ) Publishes Financial Calendar 2021 Investor Relations.

Anna kaver oro
cicero sa retorika

09:00 Pressmeddelande 19 februari 2021 Immunicum AB (publ) erhåller 8 732 8400 E-post: info@immunicum.com INVESTOR RELATIONS Jonas Rodny och

Innovation in immuno-oncology. You are here: Home News & Events Immunicum in the News New Investors Relations Firm Immunicum AB (publ) Publishes the Annual Report for 2020 12 Apr 2021; Immunicum Announces Investor Event and Conference Participation for April 07 Apr 2021; Notice of Annual General Meeting in Immunicum am (publ) 31 Mar 2021; See all Pressmeddelande. 31 januari 2018. Immunicum rekryterar Michaela Gertz som ny CFO . Immunicum AB (publ; Nasdaq Stockholm: IMMU.ST), ett bioteknikbolag som utvecklar nya immunostimulerande cancerbehandlingar för ett antal solida tumörformer, meddelar idag att Michaela Gertz börjar på bolaget som CFO från och med den 1 februari 2018.

2021-04-12 · Press Release . 12 April 2021. Immunicum AB (publ) Publishes the Annual Report for 2020. Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the

Press Release . 21 March 2018. Immunicum AB: Invitation to Investor Events . Immunicum AB (publ; IMMU.ST) a biopharmaceutical company advancing a novel, immune-priming cancer treatment against a variety of solid tumors, announced today that the Company will host two investor events in April. Investor relations. Prevas' 5 latest news.

Jonas Rodny and Carolin Wiken Paues Åberg Communications Telephone: +46 190 90 51 E-mail: ir@immunicum.com. Media Relations. Joanne Tudorica and E-mail: ir@immunicum.com. Investor Relations. Sijme Zeilemaker Head of Investor Relations & Corporate Communication Telephone: +46 8 732 8400 E-mail: ir@immunicum.com.